[Discussion] amylin is doing more work than we give it credit for
amylin is doing more work than we give it credit for. Not a hot take, just something I have not seen said plainly here. Sent a vial to Medutest because there was almost nothing on file for this compound. 99.5% against a claimed 99.0%, and I posted it because the log needs entries. The tolerability tables were more…
the interesting data is the combination, not the monotherapy
Agreed that the monotherapy numbers look modest out of context and that the context is the whole story.
[removed by moderator]
do not assume the dosing intuitions from the GLP-1 boards transfer
read the combination arms separately from the monotherapy arms
Is there any independent purity data on this compound that you have seen?
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Same view — long-acting is the engineering achievement here, and it is why the molecule exists at all.
nausea profile in the combination trials is the thing to read carefully
Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.
this is a less-travelled board and the evidence base shows it